Leerink Partnrs Analysts Boost Earnings Estimates for AxoGen

AxoGen, Inc. (NASDAQ:AXGN) – Analysts at Leerink Partnrs boosted their FY2025 earnings per share estimates for AxoGen in a research report issued on Monday, March 31st. Leerink Partnrs analyst M. Kratky now expects that the medical equipment provider will post earnings of ($0.11) per share for the year, up from their previous forecast of ($0.12). The consensus estimate for AxoGen’s current full-year earnings is ($0.29) per share. Leerink Partnrs also issued estimates for AxoGen’s FY2026 earnings at $0.04 EPS, FY2028 earnings at $0.23 EPS and FY2029 earnings at $0.34 EPS.

AXGN has been the subject of a number of other reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $24.00 price objective on shares of AxoGen in a report on Wednesday, March 5th. Canaccord Genuity Group raised their target price on shares of AxoGen from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, February 26th. Finally, Lake Street Capital assumed coverage on shares of AxoGen in a report on Monday, March 17th. They issued a “buy” rating and a $30.00 price target on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $22.60.

AxoGen Stock Down 3.7 %

Shares of AXGN opened at $17.81 on Wednesday. The business’s 50 day moving average is $18.26 and its 200 day moving average is $15.93. The company has a current ratio of 3.74, a quick ratio of 2.47 and a debt-to-equity ratio of 0.67. AxoGen has a 12-month low of $5.55 and a 12-month high of $21.00. The company has a market capitalization of $789.77 million, a PE ratio of -55.66 and a beta of 1.02.

Insider Buying and Selling at AxoGen

In other news, Director Amy Mcbride Wendell sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $20.02, for a total transaction of $100,100.00. Following the transaction, the director now owns 97,899 shares of the company’s stock, valued at approximately $1,959,937.98. The trade was a 4.86 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Erick Wayne Devinney sold 15,111 shares of the stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $17.50, for a total value of $264,442.50. Following the sale, the insider now owns 217,762 shares in the company, valued at $3,810,835. The trade was a 6.49 % decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. R Squared Ltd bought a new stake in shares of AxoGen in the 4th quarter worth about $30,000. US Bancorp DE purchased a new stake in AxoGen in the 4th quarter worth about $30,000. State of Wyoming bought a new stake in AxoGen in the fourth quarter worth about $31,000. Harvest Fund Management Co. Ltd bought a new stake in AxoGen in the fourth quarter worth about $93,000. Finally, Quantbot Technologies LP purchased a new position in shares of AxoGen during the third quarter valued at approximately $165,000. 80.29% of the stock is owned by hedge funds and other institutional investors.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.